Because c-FLIP inhibits death receptor- or anti-cancer drug-mediated apoptosis as well as activates several cytoprotective signaling pathways involved in regulating survival, proliferation, and carcinogenesis, targeting c-FLIP may be an attractive strategy for anti-cancer therapy. This evidence concerns the gene CFLAR and cancer.